The role of aromasin in the hormonal therapy of breast cancer

Pathology and Oncology Research

Volumn 8, Issue 2, 2002, Pages 87-92

  Dank, Magdolna ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Aromasin; Breast cancer; Exemestane; Hormonal therapy

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANDROSTENEDIONE; AROMATASE INHIBITOR; CYTOSTATIC AGENT; EXEMESTANE; FADROZOLE; FORMESTANE; GESTAGEN; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ALOPECIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPHONIA; FLUSHING; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTRICHOSIS; METASTASIS; POSTMENOPAUSE; REVIEW; SIDE EFFECT;

EID: 0036373044     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033716     Document Type: Review

References (37)

1. Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer
2. On the treatment of inoperable cases of carcinoma of the mamma, suggestions for a new method of treatment with illustrative cases
3. Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast
4. Hypophysectomy in man
5. Cortisone treatment of metastatic breast cancer
6. Androgens and estrogens in the treatment of disseminated mammary carcinoma
7. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474
8. Aminogluthetimide is an inhibitor or adrenal steroidogenesis: Mechanim of action and therapeutic trial
9. A possible new approach to the treatment of metastatic breast cancer: Massive doses of medroxyprogesterone acetate
10. 4-Hydroxyandrostendione in treatment of postmenopausal patients with advanced breast cancer
11. Treatment of metastatic disease
12. Comparison of biochemical activity with aromatase immunhistochemistry in human breast carcinoma
13. Aromatase inhibitors - Mechanisms of steroidal inhibitors
14. Inactivation of aromatase in vitro by 4-hydroxy-androstene-3,17-dione and 4-acetaxy-4-androstene-3,17-dione and sustained effects in vitro
15. Aromatase inhibitors and enzyme stability
16. Effects of aromatase inhibitors on the pathobiology of human breast endometrial and ovarian carcinoma
17. Biology of aromatase inhibitors: Pharmacology/endocrinology within the breast
18. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor in postmenopausal breast cancer patients
19. Exemestane (FCE 24304) a new steroidal aromatase inhibitor
20. 6-Methylenandrosta-1,4-diene-3,17-dion (FCE 24304): A new irreversible aromatase inhibitor
21. Novel aromatase and 5-reductase inhibitors
22. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A Phase I study
23. Profound suppression of plasma estrogen by megestrol acetate in postmenopausal breast cancer patients
24. Exemestane in advanced breast cancer
25. Third-line treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminogluthetimide. A Phase II multicentre multinationale study
26. Activity of exemestane (Aromasin®) in metasttic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
27. A phase II confirmatory study of antitumor efficacy and safety of exemestane (EXE) as third line hormonal treatment of postmenopausal patients (PTS) with metastatic breast cancer (MBC) refractory to tamoxifen (T) and Megace®
28. Phase II trial of exemestane as third line hormonal therapy of postmenopausal women with metastatic breast cancer
29. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer failing tamoxifen
30. A phase II study of antitumor efficacy and safety of exemestane (EXE) as a second line hormonal treatment of postmenopausal patients with metastatic breast cancer (MBC) refractory to tamoxifen (Tam)
31. Exemestane is superior to megestrol acetate following tamoxifen failure in postmenopausal women with advanced breast cancer. Results of Phase III randomised double-blind trial
32. Hormonal therapy in breast cancer and predominant visceral disease: Effectiveness of the new oral aromatase inactivator, Aromasin® (exemestane) in advanced breast cancer patients having progressed on antioestrogens
33. Exemestan (Aromasin) is active and well tolerated as first line hormonal therapy (HT) in metastatic breast cancer (MBC) patients (Pt): Result of a randomised phase II trial
34. Tamoxifen for early breast cancer: An overview of the randomised trials
35. Phase IIb study of neoadjuvant exemestan in locally advanced breast cancer